TIMP-1 and VEGF-165 Serum Concentration During First-Line Therapy of Ovarian Cancer Patients

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-10-139
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC